CLIN Clinigen Group Plc

TIDMCLIN

Clinigen Group plc

05 August 2021

5(th) August 2021

Removal of Erwinase(R) (crisantaspase) supply constraints in the United Kingdom

Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical Products and Services company, announces that Erwinase(R) (crisantaspase (Erwinia L-asparaginase)), 10,000 IU/vial, is now available for unrestricted supply in the United Kingdom ('UK'). Previous restrictions on Erwinase(R) allocation, introduced on 6 April 2021 due to supply constraints, have now been removed.

Erwinase(R) is manufactured and licensed in the UK by Porton Biopharma Limited, and available via Clinigen.

Sam Herbert, Chief Operating Officer of Clinigen, said, "We are pleased that, with our partner Porton Biopharma, we can offer unrestricted access in the UK for Erwinase. Physicians and patients can now be confident in being able to access this life-saving standard of care."

Globally, Erwinase(R) is available in the UK, France, the Netherlands, Portugal and Ireland on a commercial basis and into other markets on an unlicensed basis, and supports Clinigen's commitment to provide the right medicine to the right patient at the right time.

- Ends -

Contact details

 
 Clinigen Group plc                              Tel: +44 (0) 1283 495010 
 Sam Herbert, Chief Operating Officer            Investors@Clinigengroup.com 
  Rob Fox, VP Investor Relations and Corporate 
  Development 
 
 Numis Securities Limited - Nominated Adviser    Tel: +44 (0) 20 7260 
  & Joint Broker                                  1000 
 James Black / Garry Levin / Freddie Barnfield   Clinigen@Numis.com 
 
 RBC Capital Markets - Joint Broker              Tel: +44 (0) 20 7653 
                                                  4000 
 Marcus Jackson / Elliot Thomas 
 
 Consilium Strategic Communications              Tel: +44 (0) 20 3709 
                                                  5700 
 Mary-Jane Elliott / Matthew Cole / Matthew 
  Neal                                           Clinigen@consilium-comms.com 
 

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,000 employees across five continents in 16 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies: interacting with over 5,000 hospitals across more than 115 countries.

Erwinia L-asparaginase is marketed under the name Erwinase globally outside the United States and Clinigen is the exclusive licensed distributor

   For more information on Clinigen, please visit   http://www.clinigen.com 

About Acute Lymphoblastic Leukaemia ('ALL')

Acute lymphoblastic leukemia (ALL) is a heterogenous hematologic disease characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood and other organs. Both adults and children can get the illness, but it is most often diagnosed in younger people. The incidence in the EU is thought to be 1.28 per 1,000,000 individuals annually, with significant age-related variations.

About Porton Biopharma Limited ('PBL')

PBL is a biopharmaceutical development and manufacturing company with approximately 400 staff. It was formed in April 2015 as a spin-out company of Public Health England, and has a sole shareholder in the Department of Health and Social Care. PBL is based at Porton Down, Wiltshire, which has a long history of pharmaceutical development and manufacturing. Erwinase, the UK's anthrax vaccine, Dysport and other medical treatments have been developed at the site.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABCGDIIUGDGBS

(END) Dow Jones Newswires

August 05, 2021 02:00 ET (06:00 GMT)

Clinigen (LSE:CLIN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024

Clinigen (LSE:CLIN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024